Nicolas Girard, MD, PhD, a thoracic oncologist at the Institut Curie in Paris, France, discusses the final overall survival results from the MARIPOSA trial (NCT04487080) of amivantamab-vmjw (Rybrevant ...

(RTTNews) - Johnson & Johnson (JNJ) Thursday reported positive data from the Phase 3 MARIPOSA study evaluating rybrevant plus lazcluze versus osimertinib in the first-line treatment of patients ...

The combination of lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) demonstrated significantly improved progression-free survival (PFS), intracranial efficacy, and showed promising overall ...